IDEAS home Printed from https://ideas.repec.org/a/bdz/joimer/v2y2023i11p1-8.html

Metformin: An Oral Anti-Hyperglycaemic Agent for the Treatment of Type 2 Diabetes

Author

Listed:
  • Devajit Mohajan

    (Department of Civil Engineering, Chittagong University of Engineering & Technology, Chittagong, Bangladesh)

  • Haradhan Kumar Mohajan

    (Department of Mathematics, Premier University, Chittagong, Bangladesh)

Abstract

Metformin is one of the safest and most effective first-line glucose-lowering oral drug therapies for overweight and obese type 2 diabetes (T2D) patients, and those with normal kidney function. It is one of the drugs of Biguanide class of anti-diabetic compounds. It prevents the production of hepatic glucose, increases fatty acid oxidation, enhances insulin sensitivity, decreases lipid synthesis, and impedes gluconeogenesis. Sometimes it is used in combination with insulin or other oral medications. It should be used very carefully who have surgery, trauma, heart failure, severe kidney disease, and impaired liver functions. Some patients face side effects of Metformin and they should take it considering possible side effects of it. In this study aspect of Metformin is discussed as a guideline for the proper treatment T2D patients.

Suggested Citation

  • Devajit Mohajan & Haradhan Kumar Mohajan, 2023. "Metformin: An Oral Anti-Hyperglycaemic Agent for the Treatment of Type 2 Diabetes," Journal of Innovations in Medical Research, Paradigm Academic Press, vol. 2(11), pages 1-8, November.
    • Handle: RePEc:bdz:joimer:v:2:y:2023:i:11:p:1-8
    DOI: 10.56397/JIMR/2023.11.01
    as

    Download full text from publisher

    File URL: https://www.paradigmpress.org/jimr/article/view/857/735
    Download Restriction: no
    File URL: https://libkey.io/10.56397/JIMR/2023.11.01?utm_source=ideas
    LibKey link: if access is restricted and if your library uses this service, LibKey will redirect you to where you can use your library subscription to access this item
    ---><---

    More about this item

    Keywords

    ;
    ;
    ;
    ;

    Statistics

    Access and download statistics

    Corrections

    All material on this site has been provided by the respective publishers and authors. You can help correct errors and omissions. When requesting a correction, please mention this item's handle: RePEc:bdz:joimer:v:2:y:2023:i:11:p:1-8. See general information about how to correct material in RePEc.

    If you have authored this item and are not yet registered with RePEc, we encourage you to do it here. This allows to link your profile to this item. It also allows you to accept potential citations to this item that we are uncertain about.

    We have no bibliographic references for this item. You can help adding them by using this form .

    If you know of missing items citing this one, you can help us creating those links by adding the relevant references in the same way as above, for each refering item. If you are a registered author of this item, you may also want to check the "citations" tab in your RePEc Author Service profile, as there may be some citations waiting for confirmation.

    For technical questions regarding this item, or to correct its authors, title, abstract, bibliographic or download information, contact: Editorial Office (email available below). General contact details of provider: https://www.paradigmpress.org/ .

    Please note that corrections may take a couple of weeks to filter through the various RePEc services.

    IDEAS is a RePEc service. RePEc uses bibliographic data supplied by the respective publishers.